Journal profile · Immunology
Journal of Immunotherapy
ISSN 1524-9557 · eISSN 1537-4513 · Lippincott Williams and Wilkins Ltd. · UNITED STATES · Monthly · Founded 1997
Journal of Immunotherapy: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 2.7; JCR Q3 (journal website); hybrid open access; median 124 days to acceptance (24 articles, last 24 months); community-reported acceptance: moderate; 46 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Journal of Immunotherapy is published by Lippincott Williams and Wilkins Ltd. and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Immunotherapy and Immune Responses, CAR-T cell therapy research and Cancer Immunotherapy and Biomarkers, together about 46% of its articles. Its main subfields are Immunology. (generated from OpenAlex topic counts and CAS ranking data)
Journal of Immunotherapy features rapid publication of articles on immunomodulators, lymphokines, antibodies, cells, and cell products in cancer biology and therapy. Laboratory and preclinical studies, as well as investigative clinical reports, are presented. The journal emphasizes basic mechanisms and methods for the rapid transfer of technology from the laboratory to the clinic. JIT contains full-length articles, review articles, and short communications.
Source: LetPub
Research area (LetPub): Immunology
Editor-in-chief Steven A. RosenbergPublisher website
Main research topics OpenAlex counts of recent articles; shares are approximate
- Immunotherapy and Immune ResponsesImmunology and Microbiology22.9%
- CAR-T cell therapy researchMedicine11.8%
- Cancer Immunotherapy and BiomarkersMedicine11.4%
- Immune Cell Function and InteractionImmunology and Microbiology10.9%
- Monoclonal and Polyclonal Antibodies ResearchMedicine6.6%
- T-cell and B-cell ImmunologyImmunology and Microbiology6.1%
- Virus-based gene therapy researchBiochemistry, Genetics and Molecular Biology3.9%
- RNA Interference and Gene DeliveryBiochemistry, Genetics and Molecular Biology3.3%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Immunology | Zone 4 |
| Minor | Medicine, Research & Experimental | Zone 4 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Oncology | Zone 3 |
| Minor | Immunology | Zone 3 |
| Minor | Medicine, Research & Experimental | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Immunology | Zone 4 |
| Minor | Medicine, Research & Experimental | Zone 4 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: no
JCR / CiteScore quartiles on the journal's website
- JCR Q3 · IMMUNOLOGY · rank 116/183
- JCR Q3 · MEDICINE, RESEARCH & EXPERIMENTAL · rank 100/191
- JCR Q3 · ONCOLOGY · rank 175/333
Publisher-reported: JCR figures are Clarivate's and CiteScore figures Scopus's to confirm; both are a different system from the CAS zones.Publisher website
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 2.7LetPub ·
- Impact factor (publisher)
- 2.9Publisher website ·
- CiteScore 2026-06
- 5.4LetPub ·
- SJR 2026-06
- 1.09LetPub ·
- SNIP 2026-06
- 0.72LetPub ·
- h-index
- 89LetPub ·
- h-index
- 124OpenAlex ·
- i10-index
- 1,648OpenAlex ·
- 2-year mean citedness
- 2.23OpenAlex ·
- Self-citation rate
- 0%LetPub ·
- Share of gold OA articles
- 25.38%LetPub ·
Volume
- Articles per year
- 39LetPub ·
Articles by year OpenAlex count · 3,352 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 25 | 3 | 2 |
| 2025 | 46 | 7 | 66 |
| 2024 | 48 | 13 | 197 |
| 2023 | 51 | 24 | 437 |
| 2022 | 41 | 17 | 582 |
| 2021 | 54 | 23 | 858 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
124 daysMedian, submission to acceptance · P25–P75 92 days – 182 days
- Acceptance to online
- median 28 days (20 articles)
- Submission to online
- median 183 days
- Sample
- 24 articles with submission and acceptance dates (25 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- 6–12 weeksLetPub ·
- Average acceptance (community reports)
- ModerateLetPub ·
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
No source has fee information yet; check the journal's website.
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Profile
Publication details and official links
- Publisher
- Lippincott Williams and Wilkins Ltd.
- Country or region
- UNITED STATES
- Language
- English
- Frequency
- Monthly
- Founded
- 1997
- ISSN
- 1524-9557
- Electronic ISSN
- 1537-4513
- Latest issue on the website
- Volume 49, Issue 8 (October 2026)
- Official links
- Journal homepage ↗LetPub
- Submission system ↗LetPub
FAQ
Frequently asked questions about Journal of Immunotherapy
What CAS zone is Journal of Immunotherapy in?
In the 2025 upgraded edition of the CAS Journal Ranking, Journal of Immunotherapy is in Zone 4 of Medicine, and in Zone 4 of the minor category Immunology / Medicine, Research & Experimental / Oncology. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Journal of Immunotherapy?
The latest impact factor listed by LetPub is 2.7; CiteScore 5.4, h-index 124.
How long does peer review take at Journal of Immunotherapy?
Based on the dates recorded on 24 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 124 days (interquartile range 92–182 days); authors report an average review time of 6–12 weeks; the community-reported acceptance is “Moderate”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What JCR quartile is Journal of Immunotherapy in?
The journal's website gives JCR Q3; by category, IMMUNOLOGY Q3 (116/183), MEDICINE, RESEARCH & EXPERIMENTAL Q3 (100/191), ONCOLOGY Q3 (175/333). JCR quartiles are Clarivate's to confirm and a different system from the CAS zones; in the CAS ranking the journal is in Zone 4 of Medicine.
Which databases index Journal of Immunotherapy?
According to LetPub and DOAJ records, Journal of Immunotherapy is indexed in SCIE and Scopus.
Is Journal of Immunotherapy open access, and what is the APC?
Journal of Immunotherapy is a hybrid journal. Fee information is not available yet; check the journal's website.
Sources and updates
The facts on this page come from LetPub, OpenAlex, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .